Medaysis
Enable Innovation

DATA SHEET

Mouse Anti-EZH2/KMT6 [6G4F4]: MC0259

Intended Use: For Research Use Only

Description: EZH2 (enhancer of zeste homologue 2) or KMT6 or Enx1, is a polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. EZH2 is ubiquitously expressed during early embryo genesis, and becomes restricted to the central and peripheral nervous systems and sites of fetal hematopoiesis during later development. EZH2 and BMI-1 genes are coexpressed in Reed-Sternberg cells of Hodgkin's disease. Coexpression of BMI-1 and EZH2 is also associated with cycling cells and degree of malignancy in B-cell non-Hogkin's lymphoma. It is involved in the progression of prostate cancer, and has been identified as a marker of aggressive breast cancer.

Specifications:

Clone:	6G4F4
Source:	Mouse
Isotype:	IgG1
Reactivity:	Human
Localization:	Nucleus
Formulation:	Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC, ELISA, Flow Cyt., ICC/IF, WB

Package:

Description	Catalog No.	Size
EZH2/KMT6 Concentrated	MC0259	1 ml

IHC Procedure*:

Positive Control Tissue:	Breast, colon, larynx, lymphoma and testis cancer, 293T, HeLa
Concentrated Dilution:	25-100
Pretreatment:	Citrate pH6.0 or EDTA pH8.0 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human colon cancer stained with anti-EZH2 using DAB

References:

1. Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase. Sbirkov Y, et al. Int J Mol Sci 18:N/A, 2017.
2. MicroRNA-138 suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting EZH2 and PI3K/AKT signaling. Si F, et al. Exp Ther Med 14:1967-1974, 2017.
3. miR-143 inhibits oncogenic traits by degrading NUAK2 in glioblastoma. Fu TG, et al. Int J Mol Med 37:1627-35, 2016.
4. Significance of EZH2 expression in canine mammary tumors. Choi HJ, et al. BMC Vet Res 12:164, 2016.
5.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 510-509-3153 www.medaysis.com

© Medaysis Company